Discovery of an Orally Bioavailable NK1 Receptor Antagonist, (2S,3S)-(2-Methoxy-5-tetrazol-1-ylbenzyl)(2-phenylpiperidin-3-yl)amine (GR203040), with Potent Antiemetic Activity

Citations Over TimeTop 10% of 1995 papers

Abstract

The antiemetic, pharmacokinetic, and metabolic profile of CP-99,994, a potent NK1 receptor antagonist, has been carefully evaluated. As a result we began a medicinal chemistry program which initially identified a 3-furanyl analogue (6) with improved antiemetic potency and a methyl sulfone (5) with enhanced metabolic stability and oral bioavailability. The improved pharmacokinetic profile of methyl sulfone (5) was associated with its low lipophilicity, and a therefore a number of heterocyclic analogues with reduced log D were synthesized. Out of this program emerged 19 (GR203040), a tetrazolyl-substituted analogue. Tetrazole 19 inhibits radiation-induced emesis in the ferret with high potency when administered both subcutaneously and orally, has a long duration of action, and has high oral bioavailability in the dog. Tetrazole 19 is currently undergoing evaluation as a novel approach for the control of emesis associated with, for example, cancer chemotherapy.

Related Papers

• → Differential involvement of neurotransmitters through the time course of cisplatin-induced emesis as revealed by therapy with specific receptor antagonists(2003)250 cited
• → Optimizing antiemetic therapy in multiple-day and multiple cycles of chemotherapy(2008)21 cited
• → Neurokinin-1-Receptor Antagonists: A New Approach in Antiemetic Therapy(2006)16 cited
• → Patients treated with an NK1 receptor antagonist report less hardship due to chemotherapy-induced nausea & vomiting compared to those on standard antiemetic therapy(2001)2 cited
• → 937 Superiority of aprepitant, an oral NK1 antagonist, over standard antiemetic therapy: Reducing the impact of nausea and vomiting on patients' daily lives(2003)2 cited